Physcion Alleviates Osteoporotic Bone Loss by Inhibiting Osteoclast Formation and Promoting Osteoblast...

Area of Science:

• Pharmacology
• Biochemistry
• Bone Biology

Background:

• Osteoporosis is a bone disorder caused by imbalanced bone remodeling, with excessive resorption and insufficient formation.
• Physcion, a natural anthraquinone, has various pharmacological activities, but its role in bone remodeling is not well understood.

Purpose of the Study:

• To investigate physcion's potential in preventing osteoporotic bone loss.
• To determine physcion's effects on osteoclast and osteoblast differentiation and activity.

Main Methods:

• In vitro studies assessed physcion's effects on osteoclastogenesis and osteoblast differentiation using bone marrow cells.
• Osteoclast function and osteoblast differentiation markers were analyzed via staining, activity assays, Western blotting, and qPCR.
• In vivo studies used ovariectomy-induced osteoporotic mice treated with physcion, with bone microarchitecture analyzed by micro-CT.

Main Results:

• Physcion inhibited osteoclast formation and bone resorption by suppressing NF-κB and p38 MAPK pathways.
• Physcion promoted osteoblast differentiation by activating SMAD1/5/9 and ERK1/2 pathways.
• In vivo, physcion treatment significantly reduced bone loss in osteoporotic mice.

Conclusions:

• Physcion demonstrates dual osteoprotective effects by modulating both osteoclast and osteoblast activity.
• Physcion shows promise as a natural therapeutic agent for preventing and treating osteoporosis.